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Abstract
Inappropriate prescribing (IP) in older patients is highly prevalent and is associated with an
increased risk of adverse drug events (ADEs), morbidity, mortality and healthcare utilisation.
Consequently, IP is a major safety concern and with changing population demographics, it is likely
to become even more prevalent in the future. IP can be detected using explicit or implicit
prescribing indicators. Theoretically, the routine clinical application of these IP criteria could
represent an inexpensive and time efficient method to optimise prescribing practice. However, IP
criteria must be sensitive, specific, have good inter-rater reliability and incorporate those
medications most commonly associated with ADEs in older people. To be clinically relevant, use
of prescribing appropriateness tools must translate into positive patient outcomes, such as reduced
rates of ADEs. To accurately measure these outcomes, a reliable method of assessing the
relationship between the administration of a drug and an adverse clinical event is required. The
Naranjo criteria are the most widely used tool for assessing ADE causality, however, they are often
difficult to interpret in the context of older patients. ADE causality criteria that allow for the
multiple co-morbidities and prescribed medications in older people are required. Ultimately, the
current high prevalence of IP and ADEs is unacceptable. IP screening criteria need to be tested as
an intervention to assess their impact on the incidence of ADEs in vulnerable older patients. There
is a role for IP screening tools in everyday clinical practice. These should enhance, not replace good
clinical judgement, which in turn should be based on sound pharmacogeriatric training.
Background
Older patients often have numerous co-morbidities for
which they are prescribed multiple medications, thereby
increasing the risk of adverse drug events (ADEs) [1]. This
risk is compounded by age-related changes in physiology
and body composition, which influence drug handling
and response [2]. Furthermore, there is marked heteroge-
neity in health status and functional capacity in older peo-
ple, often making prescribing decisions complex and
challenging [2-4]. Evidence suggests that suboptimal or
inappropriate prescribing (IP) is highly prevalent in older
people and is associated with an increased risk of ADEs,
increased morbidity, mortality and healthcare utilisation
[5-9]. With changing worldwide population demograph-
ics and an aging population, IP in older people is becom-
ing a global healthcare concern [5].
IP encompasses the use of medicines that pose more risk
than benefit, particularly where safer alternatives exist. IP
also includes the misuse of medicines (inappropriate dose
or duration), the prescription of medicines with clinically
significant drug-drug and drug-disease interactions, and
importantly, the under-use of potentially beneficial med-
ications [5]. IP can be detected using explicit (criterion-
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based) or implicit (judgement-based) prescribing indica-
tors. Beers' criteria are the most widely cited explicit tool
and have dominated the international literature since
their development in the U.S. in 1991 [10]. They consist
of two lists of medications to be avoided in older people,
(a) independent of diagnosis, and (b) considering diag-
nosis, and do not address under-prescribing, drug-drug
interactions or drug class duplication. They were origi-
nally designed for older nursing home residents, but were
revised in 1997 [11] and 2002 [12] to be universally appli-
cable to older patients. More recently, the STOPP (Screen-
ing Tool of Older Persons' potentially inappropriate
Prescriptions) criteria were validated in a European setting
[13]. STOPP criteria (see additional file 1) are arranged
according to physiological systems for ease of use and
include reference to drug class duplication, drug-drug and
drug-disease interactions. They are uniquely designed for
use alongside the START (Screening Tool to Alert doctors
to the Right Treatment) criteria, which highlight under-
prescription or omission of clinically indicated, evidence-
based medications [14], thereby addressing more
domains of prescribing appropriateness than Beers' crite-
ria alone. Explicit criteria have been criticised for having
limited transferability between countries due to variations
in regional prescribing patterns and drug availability [5].
Explicit criteria must also be regularly updated in line with
evolving clinical evidence.
The Medication Appropriateness Index (MAI) [15] is an
implicit tool which measures prescribing appropriateness
according to ten criteria including indication, effective-
ness, dose, administration, drug-drug and drug-disease
interactions and cost. It does not address under-prescrib-
ing. Clinical expertise is required to apply some of the cri-
teria, resulting in variable inter-rater reliability.
Consequently, the MAI is predominantly used as a
research tool.
Prevalence of inappropriate prescribing in the 
elderly
IP is highly prevalent in older people, with up to 24% of
community-dwelling patients [16] and 40% of nursing
home residents in the United States [17] regularly receiv-
ing at least one potentially inappropriate medicine (PIM)
according to Beers' criteria. IP prevalence is somewhat
lower in Europe, though comparison between studies is
limited by differing methodologies. Under-prescribing is
even more widespread – a recent study found that 58% of
older patients do not receive one or more clinically indi-
cated medications according to START criteria [14]. Risk
factors for IP include older age, polypharmacy and multi-
ple attending physicians and pharmacists [5]. IP is associ-
ated with increased morbidity, mortality and healthcare
cost, largely because of an increased prevalence of ADEs
[5].
Adverse drug events and inappropriate 
prescribing
ADEs are defined as any injury resulting from drug ther-
apy – from appropriate care, or unsuitable or suboptimal
care [18]. ADEs include adverse reactions during normal
use of a medicine, and any harm due to medication error
whether of omission or commission. Up to 35% of com-
munity-dwelling older people experience ADEs each year
[19], the incidence being even higher amongst nursing
home residents [8]. Up to 30% of hospital admissions in
older people are related to ADEs [20]. The clinical rele-
vance of IP relates to its association with negative out-
comes including preventable ADEs. Therefore, regular
application of IP screening criteria should, hypothetically,
reduce the prevalence of ADEs and related morbidity. To
accurately measure such outcomes, reliable assessment of
the relationship between drug administration and adverse
clinical event is required, both in terms of causality and
preventability. The Naranjo criteria are often used to
assess ADE causality (see additional file 2), with inter-
rater agreement scores superior to subjective clinical
judgement [21]. However, they can be difficult to inter-
pret in the context of older patients with multiple co-mor-
bidities and medications. ADEs in older patients often
present with non-specific symptoms or geriatric syn-
dromes such as cognitive impairment or falls e.g. a fall
may be related to osteoarthritis or poor visual acuity as
well as prescription of a medication that increases falls
risk such as a benzodiazepine. The causal association can
also be weakened as the Naranjo criteria evaluate drugs
individually and do not address drug-drug interactions
(see additional file 2).
The Hallas criteria classify ADEs as preventable, probably
preventable, probably not preventable or definitely not
preventable [22]. Preventable ADEs include those arising
from the prescription of PIMs and suboptimal monitoring
and dose adjustment. Non-preventable ADEs include
allergic or idiosyncratic reactions.
The ultimate aim of IP screening tools is to optimise pre-
scribing appropriateness and reduce negative outcomes
including preventable ADEs. Therefore, the medications
listed by explicit IP tools should be those most commonly
associated with preventable ADEs in older people. Some
studies have demonstrated no increased risk of ADEs in
patients receiving Beers' criteria medications [23-25].
Some also conclude that Beers' criteria PIMs account for
only a small proportion of ADEs in older patients [25,26].
However, interpretation of such studies is difficult as
many were retrospective and lacked clinical detail, thereby
resulting in incomplete application of Beers' criteria. Fur-
thermore, many did not use rigorous ADE causality and
preventability criteria. It is possible that Beers' criteria sim-
ply do not list those medications most commonly associ-BMC Geriatrics 2009, 9:5 http://www.biomedcentral.com/1471-2318/9/5
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ated with preventable ADEs in older people, as suggested
by a recent Irish study which reported that 12% of hospi-
tal admissions were related to ADEs resulting from STOPP
criteria PIMs, with only 6% resulting from Beers' criteria
PIMs [27].
Other interventions that optimise prescribing appropri-
ateness include comprehensive geriatric assessment [28],
clinical pharmacist intervention [29], prescriber educa-
tion [30] and computerised decision support tools [31].
However, such interventions are resource intensive and
not universally available. Consequently, there is a need
for a simple, inexpensive and time-efficient screening tool
which can be used routinely to guide prescribing practice
and reduce the rate of IP in older patients. Such a tool
should be sensitive, specific, include commonly encoun-
tered ADEs and have good inter-rater reliability. To be
clinically relevant, use of such a screening tool must trans-
late into positive clinical outcomes. Specific ADE causality
assessment criteria for older people are also needed to
measure the result of such interventions.
Conclusion
Ultimately, the high prevalence of IP and preventable
ADEs in older people is unacceptable, and represents a
public health hazard likely to grow in tandem with ageing
populations. Improved undergraduate and postgraduate
training in geriatric pharmacotherapy is crucial. Though
valid IP screening tools are desirable, they should
enhance, not replace, clinical judgement. These screening
tools need to be tested as an intervention in order to assess
their impact on the incidence of ADEs in this vulnerable
population.
Additional material
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